>
Switch to:

Orgenesis PE Ratio

: At Loss (As of Today)
View and export this data going back to 2010. Start your Free Trial

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2022-01-26), Orgenesis's share price is $2.5999. Orgenesis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 was $-2.81. Therefore, Orgenesis's PE Ratio for today is At Loss.


The historical rank and industry rank for Orgenesis's PE Ratio or its related term are showing as below:

NAS:ORGS' s PE Ratio Range Over the Past 10 Years
Min: At Loss   Med: 5.77   Max: 7.73
Current: At Loss

At Loss
7.73

During the past 13 years, the highest PE Ratio of Orgenesis was 7.73. The lowest was 0.00. And the median was 5.77.


NAS:ORGS's PE Ratio is ranked lower than
99.99% of the 273 Companies
in the Biotechnology industry.

( Industry Median: 30.11 vs. NAS:ORGS: At Loss )

Orgenesis's Earnings per Share (Diluted) for the three months ended in Sep. 2021 was $-0.42. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 was $-2.81.

As of today (2022-01-26), Orgenesis's share price is $2.5999. Orgenesis's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2021 was $-2.87. Therefore, Orgenesis's PE Ratio without NRI for today is At Loss.

Orgenesis's EPS without NRI for the three months ended in Sep. 2021 was $-0.42. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2021 was $-2.87.

During the past 3 years, the average EPS without NRI Growth Rate was -50.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was -20.10% per year.

During the past 13 years, Orgenesis's highest 3-Year average EPS without NRI Growth Rate was 0.50% per year. The lowest was -611.40% per year. And the median was -2.70% per year.

Orgenesis's EPS (Basic) for the three months ended in Sep. 2021 was $-0.42. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2021 was $-2.81.


Orgenesis PE Ratio Historical Data

The historical data trend for Orgenesis's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Annual Data
Trend Nov11 Nov12 Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20
PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss 15.52

Orgenesis Quarterly Data
Nov16 Feb17 May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.83 15.52 At Loss At Loss At Loss

Competitive Comparison

For the Biotechnology subindustry, Orgenesis's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Orgenesis PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Orgenesis's PE Ratio distribution charts can be found below:

* The bar in red indicates where Orgenesis's PE Ratio falls into.



Orgenesis PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Orgenesis's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=2.5999/-2.810
=At Loss

Orgenesis's Share Price of today is $2.5999.
Orgenesis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.81.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio or PE Ratio (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Orgenesis  (NAS:ORGS) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Orgenesis PE Ratio Related Terms

Thank you for viewing the detailed overview of Orgenesis's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Orgenesis Business Description

Orgenesis logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
Executives
Sidransky David director JOHNS HOPKINS UNIVERSITY 720 RUTLAND AVENUE BALTIMORE MD 21205
Reithinger Neil officer: CFO, Treasurer and Secretary 14950 N. 83RD PLACE SUITE 1 SCOTTSDALE AZ 85260
Philips Mario director C/O ATMI, INC DANBURY CT 06810
Ferber Sarah officer: Chief Scientific Officer 17B HAHASKALA STREET TEL AVIV L3 67890
Yachin Guy director 7 ORCHARD WAY N POTOMAC MD 20854
Nanda Ashish director 2301, 23RD FLOOR, TIFFANY TOWERS CLUSTER W, JLT, DUBAI, UAE DUBAI C0 4452
Bedoret Denis officer: See Remarks 48, RUE AUGUSTE PICCARD GOSSELIES C9 6041
Universite Libre De Bruxelles other: less than 10% AVENUE F, ROOSEVELT, 50 BRUSSELS C9 1050
Theodorus Ii Sa other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Theodorus Sca other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Belenger Olivier other: less than 10% DIEWEG, 69 BRUSSELS C9 1070
Shvartz Oded 10 percent owner 130 BIRUINTEI BVD. PANTELIMON, ILFOV S5 0000000
Bultot Hugues director AVENUE DE L??HORIZON 24 WOLUWE SAINT PIERRE C9 1150
Buyse Chris Georges Frans director BAILLET LATOURLEI 119A BRUSSELS C9 2390
Tenne Joseph officer: CFO Treasurer Secretary 6225 NEIL ROAD, SUITE 300 C/O ORMAT TECHNOLOGIES, INC. RENO NV 89511

Orgenesis Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)